What is the 13F Pro Quality Score for MASI?

13F Pro ranks MASIMO CORP (MASI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MASI's current score at https://13fpro.ai/research/MASI (free sign-up required for the full ranking).

Where does 13F Pro source MASI data?

All MASIMO CORP fundamentals and ownership data come directly from SEC EDGAR. MASIMO CORP files with the SEC under CIK 937556. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MASI in?

MASIMO CORP (MASI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MASI research updated on 13F Pro?

MASI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MASIMO CORP(MASI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 937556 MASI stock profile & AI dashboard →

13F Pro Quality Score

47.1/100

Rank #1,610 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

81.1/100

Profitability

21.9/100

Balance Sheet

18.3/100

Earnings Quality

30.0/100

Free Cash Flow

68.0/100

Institutional Flow

30.2/100

Revenue Scale

57.7/100

Dilution Risk

38.5/100

MASI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MASIMO CORP (MASI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MASI at 47.1/100 on a 32-signal composite quality model, placing it at rank #1,610 of 2,879 stocks — the bottom half of the AI-ranked universe. MASI scores in the top quartile across revenue growth (81.1). Areas of concern include balance sheet strength (18.3) and profitability (21.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 38.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), MASIMO CORP reports quarterly revenue of $403.6M, net income of $57.1M, an operating margin of 19.2%. Top institutional holders of MASI by reported 13-F value include BlackRock,, Politan Capital Management, Pentwater Capital Management, based on the most recent SEC filings. MASI trades on the Nasdaq exchange and files with the SEC under CIK 937556. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MASI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MASIMO CORP directly from SEC EDGAR. MASIMO CORP's 13F Pro composite quality score has ranged between 8 and 72 since 2021, currently 47.1 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about MASIMO CORP

Quirks, history, and lore behind MASI — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical technology company · mid-cap · listed on Nasdaq · headquartered in Southern California.
2
The Numbers
Annual revenue in the range of roughly $2 billion, built almost entirely on selling hardware, sensors, and software to hospitals that need to monitor patients continuously.
3
The History
Founded in the late 1990s, it spent years fighting a high-profile patent battle against a much larger rival — and won a landmark verdict that put the industry on notice.
4
The Secret
Its core innovation was reinventing pulse oximetry — the little clip that reads your blood oxygen — to work accurately even on patients in motion or with poor circulation.
5
The Lore
Its founder and CEO made headlines by purchasing a famous consumer audio brand, sparking a messy boardroom battle with investors who thought he'd gone wildly off-script.
6
The Giveaway
If you've ever had a rainbow-colored sensor clipped to your finger in a hospital, there's a good chance it said "SET" technology on the box — this Irvine company owns that standard.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$403.6M

Net Income

Q1 2026

$57.1M

Free Cash Flow

Q1 2026

$41.0M

Operating Margin

Q1 2026

19.2%

D/E Ratio

Q1 2026

0.59

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+64.3% YoY

$2.04BFY 2022

FY18 $858.3MFY19 $937.8MFY21 $1.24BFY22 $2.04B

Net Income

-37.5% YoY

$143.5MFY 2022

FY18 $193.5MFY19 $196.2MFY21 $229.6MFY22 $143.5M

Operating Income

-23.9% YoY

$210.0MFY 2022

FY18 $208.0MFY19 $221.2MFY21 $275.8MFY22 $210.0M

EPS (Diluted)

-34.7% YoY

$2.60FY 2022

FY18 $3.45FY19 $3.44FY21 $3.98FY22 $2.60

Total Assets

+70.1% YoY

$3.21BFY 2022

FY18 $1.15BFY19 $1.40BFY21 $1.89BFY22 $3.21B

Total Debt

$986.9MFY 2022

FY18 —FY19 —FY21 $0.00FY22 $986.9M

Op. Cash Flow

-88.9% YoY

$29.4MFY 2022

FY18 $239.5MFY19 $221.6MFY21 $264.6MFY22 $29.4M

Metric	FY 2022	FY 2021	FY 2019	FY 2018	FY 2017	FY 2016
Revenue	$2.04B +64.3%	$1.24B +32.1%	$937.8M +9.3%	$858.3M +8.6%	$790.2M +10.9%	$712.9M
Net Income	$143.5M -37.5%	$229.6M +17.0%	$196.2M +1.4%	$193.5M +55.1%	$124.8M -59.9%	$311.1M
Operating Income	$210.0M -23.9%	$275.8M +24.7%	$221.2M +6.3%	$208.0M +13.2%	$183.8M -57.8%	$435.9M
EPS (Diluted)	$2.60 -34.7%	$3.98 +15.7%	$3.44 -0.3%	$3.45 +54.7%	$2.23 -61.9%	$5.85
Total Assets	$3.21B +70.1%	$1.89B +35.2%	$1.40B +20.9%	$1.15B +27.5%	$905.4M +10.3%	$820.5M
Total Debt	$986.9M	$0.00	—	—	—	$0.00
Operating Cash Flow	$29.4M -88.9%	$264.6M +19.4%	$221.6M -7.5%	$239.5M +327.3%	$56.1M -86.6%	$419.1M

AI Insight: MASI Financial Trends

MASI has steadily reduced debt from $852M to $465M while maintaining stable revenues around $370-410M, but equity declined $580M from peak.

• Total debt decreased consistently from $852M in Q2 2024 to $465M in Q2 2026, a $387M reduction.

• Operating income turned positive and stabilized at $77-84M in recent quarters after losses in Q3-Q4 2024.

• Revenue recovered from Q3 2024's $38M low to stabilize around $370-410M range through Q2 2026.

⚠ Equity declined from $1,463M peak in Q3 2024 to $789M in Q2 2026, a $674M decrease.

⚠ Operating cash flow remains volatile, ranging from $26M to $74M with no clear improving trend.

AI Insight: MASI Ratio Trends

Masimo achieved sustained operating margin recovery from -8.0% in Q4 2024 to 19.2% in Q2 2026, but net profitability remains volatile with negative margins in three of the last eight quarters.

• Operating margin dramatically improved from -8.0% in Q4 2024 to 19.2% in Q2 2026, maintaining above 17% for three consecutive quarters.

• ROIC recovered from -6.2% in Q4 2024 to 24.7% in Q2 2026, demonstrating strong capital efficiency improvement.

• Net profit margin remains highly volatile, swinging from -94.9% in Q4 2024 to 16.6% in Q1 2026.

⚠ Net margins turned negative again in Q3 2025 at -27.0% despite strong 22.5% operating margins, indicating below-the-line volatility.

⚠ Debt-to-equity ratio increased to 0.74 in Q1 2026 from 0.59 in Q2 2026, reversing recent deleveraging trend.

Get alerted when MASI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MASIMO CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MASI

BlackRock, Inc.
$826.1M4,644,578 sh
Politan Capital Management LP
$816.4M4,589,648 sh
Pentwater Capital Management LP
$564.9M3,176,000 sh
BARCLAYS PLC
$488.1M2,743,985 sh
HBK INVESTMENTS L P
$458.2M2,576,109 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$416.7M2,342,790 sh
VANGUARD CAPITAL MANAGEMENT LLC
$364.6M2,050,045 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$357.0M2,006,861 sh
FMR LLC
$258.1M1,450,823 sh
STATE STREET CORP
$255.7M1,437,724 sh

Fund	Value	Shares
BlackRock, Inc.	$826.1M	4,644,578
Politan Capital Management LP	$816.4M	4,589,648
Pentwater Capital Management LP	$564.9M	3,176,000
BARCLAYS PLC	$488.1M	2,743,985
HBK INVESTMENTS L P	$458.2M	2,576,109
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$416.7M	2,342,790
VANGUARD CAPITAL MANAGEMENT LLC	$364.6M	2,050,045
VANGUARD PORTFOLIO MANAGEMENT LLC	$357.0M	2,006,861
FMR LLC	$258.1M	1,450,823
STATE STREET CORP	$255.7M	1,437,724

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MASI on your watchlist

Track score changes the day MASIMO CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MASI a good stock to buy?

13F Pro's AI-powered analysis of MASIMO CORP (MASI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MASI are available on the MASI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MASI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MASI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MASIMO CORP's investment landscape.